Vimarsana
Biggest News Aggregation in the World

Page 31 - Poster Presentation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Poster Presentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Poster Presentation Today - Breaking & Trending Today

Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of ... - Vimarsana News

Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020 - Vimarsana News

Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020

Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020 Amgen today announced new data from its oncology pipeline in lung cancer will be presented during the 2020 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer taking place virtually from Jan. 28-31, 2021 . Phase 2 data from the CodeBreaK 100 clinical study, evaluating investigational sotorasib in patients with KRAS G12C -mutated advanced non-small cell lung cancer … Amgen (NASDAQ:AMGN) today announced new data from its oncology pipeline in lung cancer will b...

GEMoaB Announces Clinical Data Presentations on Their Lead Asset UniCAR-T-CD123 in relapsed/refractory AML at the Upcoming EHA-EBMT 3rd European CAR T-Cell Meeting - Vimarsana News

GEMoaB Announces Clinical Data Presentations on Their Lead Asset UniCAR-T-CD123 in relapsed/refractory AML at the Upcoming EHA-EBMT 3rd European CAR T-Cell Meeting

Share this article DRESDEN, Germany, Jan. 7, 2021 /PRNewswire/ -- GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to- treat cancers, today announced the acceptance of two presentations on clinical data from the ongoing Phase I study of their lead asset UniCAR-T-CD123 in relapsed/refractory acute myeloid leukemia (rrAML) at the 2021 EHA-EBMT 3rd European CAR T-Cell Meeting, being held from February 4-6.  So far, CAR-T cell therapy in AML has been impacted by the lack of antigens differentially expressed on malignant blasts. Targetin...